Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: A case series

Inflammatory Bowel Diseases

Volumn 18, Issue 8, 2012, Pages 1488-1492

  Absah, Imad ^a   Faubion, William A ^a  

^a MAYO CLINIC   (United States)

Author keywords

adverse effects; Crohn's disease; inflammatory bowel diseases; methotrexate; tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; TACROLIMUS;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; HEADACHE; HUMAN; INFUSION RELATED REACTION; MALE; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; REVIEW; SCHOOL CHILD; SEX RATIO; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84863945010     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21885     Document Type: Review

References (36)

1. Loftus EV Jr,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504-1517.
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5: 1424-1429.
3. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med. 1980; 302: 981-987.
4. Dubinsky MC,. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol. 2004; 2: 731-743.
5. Stephens MC, Baldassano RN, York A, et al. The bioavailability of oral methotrexate in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2005; 40: 445-449.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
7. Faubion WA Jr, Bousvaros A,. Medical therapy for refractory pediatric Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 1199-1213.
8. Tung J, Loftus EV, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2006; 12: 1093-1100.
9. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132: 863-873.
10. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007; 13: 1024-1030.
11. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med. 1995; 332: 292-297.
12. Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. Am J Gastroenterol. 2007; 102: 2804-2812.
13. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: a French multicenter study. Inflamm Bowel Dis. 2006; 12: 1053-1057.
14. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med. 2000; 342: 1627-1632.
15. Wahed M, Louis-Auguste JR, Baxter LM, et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment Pharmacol Ther. 2009; 30: 614-620.
16. Ravikumara M, Hinsberger A, Spray CH,. Role of methotrexate in the management of Crohn disease. J Pediatr Gastroenterol Nutr. 2007; 44: 427-430.
17. Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. J Pediatr Gastroenterol Nutr. 2009; 48: 526-530.
18. Schröder O, Blumenstein I, Stein J,. Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study. Eur J Gastroenterol Hepatol. 2006; 18: 11-16.
19. Kappelman MD, Crandall WV, Colletti RB, et al. Short pediatric Crohn's disease activity index for quality improvement and observational research. Inflamm Bowel Dis. 2011; 17: 112-117.
20. Kelsen JR, Kim J, Latta D, et al. Recurrence rate of clostridium difficile infection in hospitalized pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17: 50-55.
21. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004; 31: 645-648.
22. Balis FM, Mirro J Jr, Reaman GH, et al. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol. 1988; 6: 1882-1886.
23. Cronstein BN,. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005; 57: 163-172.
24. Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998; 102: 322-328.
25. Doyle MK, Rahman MU, Han C, et al. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measuresa pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin Arthritis Rheum. 2009; 39: 123-131.
26. Zintzaras E, Dahabreh IJ, Giannouli S, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. Clin Ther. 2008; 30: 1939-1955.
27. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009; 60: 2272-2283.
28. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601-608.
29. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007; 56: 1226-1231.
30. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009; 30: 210-226.
31. Willot S, Noble A, Deslandres C,. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center. Inflamm Bowel Dis. 2011 [Epub ahead of print].
32. Charpignon C, Beau P,. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Gastroenterol Clin Biol. 2008; 32: 153-157.
33. von Roon A, Reese G, Teare J, et al. The risk of cancer in patients with Crohn's disease. Dis Colon Rectum. 2007; 50: 839-855.
34. Sokol H, Beaugerie L,. Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009; 58: 1427-1436.
35. Shale M, Kanfer E, Panaccione R, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008; 57: 1639-1641.
36. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr. 1998; 132: 830-835.